DS
CRDF icon

David Shaw’s Cardiff Oncology CRDF Stock Holding History

David Shaw’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,806
Closed -$64K – 5392
2022
Q1 		$64K Buy
+25,806
New +$91.3K ﹤0.01% 5082
2021
Q1 		– Sell
-12,274
Closed -$221K – 4108
2020
Q4 		$221K Buy
+12,274
New +$216K ﹤0.01% 3705
2017
Q1 		– Sell
-250
Closed -$38K – 3332
2016
Q4 		$38K Buy
+250
New +$58.4K ﹤0.01% 3393
2016
Q3 		– Sell
-210
Closed -$68K – 3389
2016
Q2 		$68K Buy
+210
New +$72.3K ﹤0.01% 3278
2015
Q4 		– Sell
-176
Closed -$72K – 3814
2015
Q3 		$72K Sell
176
-863
-83% -$452K ﹤0.01% 3637
2015
Q2 		$759K Buy
+1,039
New +$737K ﹤0.01% 2896

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

David Shaw's CRDF Position: Q2 2022 in Review

David Shaw sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 25,806 shares — an estimated $64K sold.

David Shaw first reported a position in CRDF in Q2 2015 and held it in 6 quarters. The position peaked at $759K in Q2 2015. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • David Shaw reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 25,806 Cardiff Oncology shares in Q2 2022, an estimated $64K.
  • David Shaw first reported a position in Cardiff Oncology in Q2 2015 and held it in 6 quarters.
  • David Shaw's Cardiff Oncology position peaked at $759K in Q2 2015.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.